The incidence, treatment and prognosis of cervical carcinoma in young women: a retrospective analysis of 4,975 cases in Japan

Objective: To determine the clinical characteristics of patients (young women) with cervical carcinoma aged less than 35 years. Methods: Data from patients who were treated for cervical carcinomas from 1990 to 2000 in the Kinki District were retrospectively investigated for clinical stage, histologic type, treatment procedure and prognosis. Results: Of a total of 4,975 cases, 441 patients were aged less than 35 years old. The incidence of cervical carcinoma in these women was 7.9% from 1990 to 1995, 9.1% from 1996 to 2000, and 9.5% from 2001 to 2005. FIGO Stage I included 374 cases, followed by, 49 in Stage II, 11 in Stage III, and seven in Stage IV. Squamous cell carcinoma incidence was 80.7% and nonsquamous cell carcinoma incidence was 19.3%. Several types of surgery were performed in patients with Stage I and II, while patients with Stage III and IV were treated with radiotherapy and/or chemotherapy without any type of surgery. In patients who underwent lymphadenectomy, 21.1% cases had nodal involvement. The 5-year survival rate was 95% for Stage I disease, 73% for Stage II, 68% for Stage III, and 19% for Stage IV. Conclusion: The incidence of cervical carcinoma in young women slightly increased from 1990 to 2005. The prognosis of cervical carcinoma tends to be better in young women than in older patients, especially in Stage III disease.

Young women; Cervical carcinoma; Incidence, prognosis.

[1] Marugame T., Hamashima C.: “Mortality trend of uterine cancer in Japan 1960-2000”. Jap. J. Clin. Oncol., 2004, 34, 55.

[2] Ioka A., Tsukuma H., Ajiki W., Oshima A.: “Influence of age on cervical cancer survival in Japan”. Jpn. J. Clin. Oncol., 2005, 35, 464.

[3] Ioka A., Tsukuma H., Ajiki W., Oshima A.: “Trends in uterine cancer incidence in Japan 1975-98”. Jpn. J. Clin. Oncol., 2003, 33, 645.

[4] Marugame T., Matsuda T., Kamo K., Katanoda K., Ajiki W., Sobue T. et al.: “Cancer incidence and incidence rates in Japan in 2001 based on the date from 10 population-based cancer registries”. Jpn.

[5] Meanwell C.A., Kelly K.A., Wilson S., Roginski C., Woodman C., Griffiths R., Blackledge G.: “Young age as a prognostic factor in cervical cancer: analysis of population based data from 10022 cases”. Br. Med. J., 1988, 296, 386.

[6] Ito T., Ishizuka T., Suzuki K., Ikoma Y., Saito J., Onuma M. et al.: “Cervical cancer in young Japanese women”. Arch. Gynecol. Obstet., 2000, 264, 68.

[7] Bulk S., Visser O., Rozendaal L., Verheijen R.H.M., Meijer C..J.L.M.: “Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women”. Int. J. Cancer, 2005, 113, 1005.

[8] Pamela G., Hai-Yen Sung, Sawaya G.F.: “Changes in cervical incidence after three decades of screening US women less than 30 years old”. Obstet. Gynecol., 2003, 102, 765.

[9] Hemminki K., Li X., Mutanen P.: “Age-incidence relationships and time trends in cervical cancer in Sweden”. Eur. J. Epidemiol., 2001, 17, 323.

[10] Liu S., Semenciw R., Probert A., Mao Y.: “Cervical cancer in Canada: Changing patterns in incidence and mortality”. Int. J. Gynecol. Cancer, 2001, 11, 24.

[11] Murrell D.S., Helm C.W., Bourne H.: “Carcinoma of the cervix in women up to 35 years of age”. Clin. Oncol., 1990, 2, 260.

[12] Rutledge F.N., Mitchell M.F., Munsell M., Bass S., McGuffee V., Atkinson N.: “Youth as a prognostic factor in cancer of the cervix: a matched analysis”. Gynecol. Oncol., 1992, 44, 1230.

[13] Mariani L., Iacovelli A., Vincenzoni C., Diatallevi F.F., Atlante M., Lombardi A.: “Cervical cancer in young patients: Clinical and pathological variables”. Int. J. Gynecol. Obstet., 1993, 41, 61.

[14] Serur E., Fruchter R.G., Maiman M., McGuire J., Arrastia C.D., Gibbon D.: “Age, substance abuse, and survival of patients with cervical carcinoma”. Cancer, 1995, 75, 1530.

[15] Clark M.A., Naahas W., Marker R.J., Dodson M.G.. “Cervical cancer: women aged 35 and younger compared to women aged 36 and older”. Am. J. Clin. Oncol., 1991, 14, 352.

[16] Chen R.J., Lin Y.H., Chen C.A., Huang S.C., Chow S.N., Hsieh C. Y.: “Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan”. Gynecol. Oncol., 1997, 73, 184.

[17] Kosary C.: “FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina”. Semin. Surg. Oncol., 1994, 10, 31.

[18] Piver M.S., Rutledge F., Smith J.P.: “Five classes of extended hysterectomy for women with cervical cancer”. Obstet. Gynecol., 1974, 44, 215.

[19] Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W. T., Heintz A.P.M. et al.: “Carcinoma of the cervix uteri”. J. Epidemiol. Biostat., 2001, 6, 5.

[20] Greer B.E., Koh W.J.: “Diagnosis and treatment of cervical carcinomas. ACOG practice bulletin”. Int. J. Gynecol. Obstet., 2002, 78, 79.

[21] The report of tumor board of JSOG. Acta Obstet. et Gyn. Japon-ica, 2007, 59, 901.

[22] Green J.A., Kirwan J.M., Tierney J.F., Symonds P., Frescol L., Collingwood M.M. et al.: “Survival and recurrence after concominant chemotherapy and radiotherapy for cancer of the uterine cervix: a systemic review and meta-analysis”. Lancet, 2001, 358, 781.

[23] Lukka H., Hirte H., Fyles A.: “Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancera meta-analysis”. Clin. Oncol., 2002, 14, 203.

[24] Vermorken J.B.: “The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review”. Int. J. Gynecol. Cancer, 1993, 3, 129.

[25] Tierney J.: “Neoadjuvant chemotherapy for locally advanced cer-vical cancer: a systematic review and meta-analysis of individual patient data from 21 randomized trials”. Eur. J. Cancer, 2003, 39, 2470.

[26] Kokawa K., Mabuchi Y., Tanaka K., Yagi S., Yata C., Umesaki U.: “Apoptosis in cervical carcinoma after balloon occluded arterial infusion of anticancer drugs”. Anticancer Res., 2006, 26, 1413.

[27] Tanaka T., Kokawa K., Umesaki U.: “Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squa-mous cell carcinoma: a pilot study”. Eur. J. Gynaec. Oncol., 2005, 26, 605.

[28] Sardi J.E., Giaroli A., Sananes C., Ferreira M., Soderini A., Bermundes A. et al.: “Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results”. Gynecol Oncol., 1997, 67, 61.

[29] Benedetti-Panici P., Greggi S., Colombo A., Amoroso M., Smaniotto D., Giannarelli D. et al.: “Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study”. J. Clin. Oncol., 2002, 20, 179.

[30] Kokawa K., Nishimura R., Fujii T., Umesaki N.: “Neoadjuvant chemotherapy with irinotecan and mitomycin-C for locally advanced squamous cell carcinoma of the uterine cervix”. Anti-caner Res., 2007, 27, 2721.

[31] Napolitano C., Imperano F., Mossa B., Framarino M.L., Marziani R., Marzetti L.: “The role of neoadjuvant chemotherapy for squa-mous cell cervical cancer (Ib-IIIb): a long-term randomized trial”. Eur. J. Gynecol. Oncol., 2002, 24, 51.

[32] Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systemic review and meta-analysis of individual patient data from 21 randomized trials. Eur.J. Cancer, 2003, 39, 2470.